Here is the design of a clinical trial:

Official Title: Diagnostic Accuracy of Contrast-enhanced Diffusion-weighted MRI for Liver Metastases of Pancreatic Cancer: Towards Adequate Staging and Follow-up of Pancreatic Cancer

Included conditions:
- Pancreatic Neoplasms

Study Armgroups:
- {'label': 'Patients with (suspected) PDAC', 'type': 'OTHER', 'description': 'Patients with (suspected) pancreatic cancer will undergo additional Contrast-enhanced Diffusion-weighted MRI (CE-DW-MRI) within two weeks from the CECT.\n\nSuspected liver lesions on CECT and/or CE-DW-MRI will be biopsied to obtain histopathology as reference standard. For liver lesions without histopathologic proof of metastases a paired follow-up CECT and CE-DW-MRI serve as a composite reference standard. Follow up CECT and CE-DW-MRI will be performed in all patients at 3, 6, and 12 months.', 'interventionNames': ['Diagnostic Test: Contrast-enhanced Diffusion-weighted MRI']}

Interventions:
- {'type': 'DIAGNOSTIC_TEST', 'name': 'Contrast-enhanced Diffusion-weighted MRI', 'description': 'An MRI scan enhanced with intravenous contrast and with diffusion imaging at several B-values', 'armGroupLabels': ['Patients with (suspected) PDAC']}

Primary Outcomes:
- {'measure': 'Diagnostic accuracy of CE-DW-MRI', 'description': 'Sensitivity and Specificity of CE-DW-MRI for the detection of liver metastases in patients with pancreatic cancer compared to CECT.', 'timeFrame': 'Baseline'}

Please estimate the sample size based on the assumption: 
Confidence interval of 95% (Z = 1.96), α = 0.05, expected percentage of patients with liver metastases is approximately 40%, and an expected inclusion rate of 80% (assuming 20% dropout rate).
Sample size
          The sample size for the study was calculated for the primary endpoint (sensitivity and specificity of MRI for the detection of liver metastases).
          The sample size is calculated based on a method for power calculations for diagnostic studies described by Jones et al. [30]. Based on literature and our previously performed retrospective study [9, 31â35] we estimate the sensitivity of MRI will be approximately 90%. In literature the specificity for MRI is usually higher than the sensitivity, therefore we based our sample size calculation on the sensitivity only. With an expected sensitivity of 90%, confidence interval of 95% (Zâ=â1.96) and Î±â=â0.05, 138 patients with metastasis are required for analysis. Based on literature the expected percentage of patients with liver metastases is approximately 40% [3, 36]. With an expected inclusion rate of 80% (assuming 20% cannot be analyzed optimally, e.g. because no representative liver biopsies could be acquired, mortality before first follow-up or withdrawal) we need approximately 433 patients. In case the proportion of patients with metastases is not equal to 40% in our cohort, we will include until we reach 138 patients with liver metastasis or up to a maximum total of 465 patients.